Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|December 17, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-01-06-2016
- Volume 12
- Issue 1
Recipharm Signs Agreement to Manufacture Liproca Depot
Author(s)Pharmaceutical Technology Editors
Recipharm has signed an agreement with Sweddish pharmaceutical company LIDDS for the production scale up and manufacture of LIDDS’ Liproca depot for the treatment of prostate cancer.
Advertisement
Recipharm announced that it has signed an agreement with Swedish pharmaceutical company LIDDS for the production scale up and manufacture of LIDDS’ Liproca depot for the treatment of prostate cancer.
The patented technology, Liproca depot, is a novel bioresorbable, biocompatible, and locally injectable modified-release formulation of 2-hydroxyflutamid, prepared as a paste, prior to injection, and which cures shortly after injection. The product is delivered in a prefilled syringe, which also serves as mixing equipment of the paste prior to injection.
This agreement marks an important step in the preparation of a Phase IIb study of Liproca depot, which is expected to begin in 2016. In connection with the agreement, Recipharm has invested SEK 5 million in a private placement, making it the third largest shareholder of LIDDS.
Source:
Articles in this issue
almost 11 years ago
CMO Consolidation Pace May Slow Downalmost 11 years ago
Branded and Generic APIs Look to Strong 2016almost 11 years ago
Sun Pharmaceutical Issued Warning Letter for Microbial Violationsalmost 11 years ago
Collaboration Seeks to Reduce Animal Testingalmost 11 years ago
GENEWIZ Acquires Beckman Coulter Gene Servicesalmost 11 years ago
AMRI Acquires Whitehouse Laboratoriesalmost 11 years ago
Quotient Clinical Acquires Co-Formulate Limitedalmost 11 years ago
Capsugel to Acquire Xcelience and Powdersizealmost 11 years ago
FDA Warns of Potential Baclofen API Contaminationalmost 11 years ago
Althea Expands Biological Drug Product Manufacturing OperationsAdvertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
Complying with International Pharmacopoeias
5